ProCE Banner Activity

Principais estudos sobre HIV que influenciam a minha prática após a CROI 2023

Slideset

Baixe os slides para revisar os resumos dos principais estudos sobre HIV da CROI 2023, incluindo resultados de estudos sobre estratégias de prevenção, terapias de ação prolongada, eventos adversos da TARV, terapias de segunda linha e coinfecção.

Released: March 23, 2023

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Joseph J. Eron Jr.

Joseph J. Eron Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic, San Francisco General Hospital
San Francisco, California

Princy N. Kumar

Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Queen Mary University of London
The Royal London Hospital
London, United Kingdom

Babafemi Taiwo

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Cheif
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD: consultor/conselheiro/palestrante: Gilead, GSK, Merck, Theratechnologies, ViiV; pesquisador: Gilead Sciences, GSK, ViiV.

Joseph J. Eron Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron Jr., MD: consultor/conselheiro/palestrante: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV; pesquisador: Gilead Sciences, ViiV.

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic, San Francisco General Hospital
San Francisco, California

Monica Gandhi, MD, MPH, não tem relações financeiras relevantes a divulgar.

Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP: consultora/conselheira/palestrante: Johnson & Johnson, Thera, ViiV; pesquisadora: Merck; ações e opções de ações individuais negociadas publicamente: Gilead, Pfizer.

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Queen Mary University of London
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, GSK, MSD, ViiV; researcher: AstraZeneca, Gilead, GSK, MSD, ViiV.

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Cheif
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultor: Gilead, GlaxoSmithKline, Johnson & Johnson, ViiV.